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Abstract
Purpose Chronic inflammation has been implicated in the
etiology of various chronic diseases. We previously found
that certain urinary isoflavones are associated with markers
of inflammation. In the present study, we examined the
associations of serum C-reactive protein (CRP) and white
blood cell (WBC) count with lignans, which are more
frequent in the Western diet than isoflavones.
Methods Our analysis included 2,028 participants of
NHANES 2005–2008 and 2,628 participants of NHANES
1999–2004 aged 18 years and older. The exposures of
interest were urinary mammalian lignans (enterodiol and
enterolactone). Outcome variables were two inflammatory
markers (CRP [B10 mg/L] and WBC [C3.0 and B11.7
(1,000 cells/lL)]). Log-transformed CRP concentration
and WBC count by log-transformed creatinine-standard-
ized concentrations of mammalian lignans were used for
linear regression.
Results Statistically significant inverse associations of
urinary lignan, enterodiol, and enterolactone concentrations
with circulating CRP and WBC counts were observed in the
multivariate-adjusted models: In NHANES 2005–2008, per
one-percent increase in lignan concentrations in the urine,
CRP concentrations and WBC counts decreased by 8.1 %
(95 % CI -11.5, -4.5) and 1.9 % (95 % CI -2.7; -1.2),
respectively. Per one-percent increase in enterodiol and en-
terolactone, WBC counts decreased by 2.1 % (95 % CI
-2.8, -1.3) and 1.3 % (95 % CI -1.9, -0.6), respectively.
In NHANES 1999–2004, analogous results were 3.0 %
(95 % CI -5.6, -0.3), 1.2 % (95 % CI -2.0; -0.4), 1.0 %
(95 % CI -1.8, -0.2), and 0.8 % (95 % CI -1.4, 0.2).
Conclusions Mammalian lignans were inversely associ-
ated with markers of chronic inflammation. Due to the
cross-sectional design, our findings require confirmation in
prospective studies.
Keywords Mammalian lignans  C-reactive protein 
White blood cell count  Cross-sectional study
Introduction
Low-grade chronic inflammation has been postulated to
play an important role in the development of chronic dis-
eases, i.e., cardiovascular disease, type 2 diabetes mellitus,
and various types of cancer [1]. C-reactive protein (CRP),
which is produced in the liver in response to elevated
cytokine levels in the context of an inflammatory stimulus,
is used as biomarker of acute and chronic inflammation [2].
Similarly, elevated white blood cell (WBC) count is a
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marker of systemic inflammation [3]. An increased risk of
chronic diseases has been observed with elevated CRP
levels and WBC counts [4–6]. CRP concentration and
WBC count are easy to measure, and they do not have
diurnal or seasonal variation [6]. However, they are very
responsive to acute infections and are elevated in individ-
uals with myocardial infarction, surgery, burns, malig-
nancies, etc [6]. High circulating CRP concentrations have
indeed been shown to be associated with the risk of some
types of cancer [7] and also cancer survival [8]. Further-
more, elevated blood levels of CRP and WBC are associ-
ated with obesity, smoking, a lower level of physical
activity, no or heavy alcohol intake (only CRP), and
estrogen use [6, 9–19], all of which are cancer risk factors.
Intakes of some nutrients or foods (n-3 polyunsaturated
fatty acids, fiber, flavonoids, antioxidants, vegetables,
fruit, and fish, etc.), on the contrary, have been reported
to be inversely associated with serum CRP concentration
[20–26].
Phytoestrogens are plant constituents found in many
foodstuffs. They may act as weak estrogens [27], but also
as antioxidants and anti-inflammatory agents, suggesting a
possible CRP level- and WBC count-lowering role [28].
The main groups of phytoestrogens are lignans, isoflav-
ones, and coumestans [27, 29]. The major lignans are
matairesinol, secoisolariciresinol, pinoresinol, lariciresinol,
and syringaresinol. The major isoflavones are genistein and
daidzein. The mammalian lignans’ enterolactone and en-
terodiol can be formed by the gut microflora from lignan
plant precursors; and the isoflavones equol and O-DMA
from daidzein [27].
Only a few studies exist on the association between
lignans and CRP concentrations, and the results are not
consistent [30–32] and need further investigation.
In previous studies, the health effects of phytoestrogens
were mainly studied by estimating the dietary intake of
these plant constituents by study participants or by testing
dietary supplements or enriched foods. However, measur-
ing the concentration of phytoestrogens in urine considers
interindividual variations in microbial synthesis [33] and is
independent of errors due to imprecise dietary assessments
and databases.
In a recent publication, we have shown that higher
excretion of certain soy isoflavonoids were associated with
decreased CRP concentration and WBC counts in adults in
the United States in the National Health and Nutrition
Survey (NHANES) 2005–2008 [34]. However, the intake
of soy products that are the major contributor to isoflavone
intake is low in Western societies compared with Asian
populations. The intake of lignans, on the other hand, is
higher in Western societies. Therefore, we examined in the
present study whether mammalian lignans, i.e., enterolac-
tone and enterodiol, are associated with markers of
inflammation. To be able to compare our results with the
previous results by Nicastro et al. [34], we decided to show
associations for the NHANES period 2005–2008 and
1999–2004 separately, as Nicastro et al. had analyzed the
period 2005–2008. To our knowledge, this is the first study
to investigate the association of urinary mammalian lignan
concentration with circulating CRP and WBC counts.
Methods
Study population
NHANES is an on-going cross-sectional study representa-
tive of the population of the United States (US), which is
carried out by the National Center for Health Statistics
(NCHS). Data are released for two succeeding years (i.e.,
1999/2000, 2001/2002, etc.). In NHANES, the health and
nutritional status of adults and children in the US is
assessed by interviews and physical examinations.
The NHANES interview includes demographic, socio-
economic, dietary, and health-related questions. The
examination part consists of medical, dental, and physio-
logical measurements, as well as laboratory tests. All data
are anonymized. The sample for the survey represents the
US population of all ages. A complex, multistage, proba-
bility sampling design is used to select participant repre-
sentative of the civilian, non-institutionalized US
population. To produce reliable statistics, NHANES over-
samples individuals 60 years and older, African Ameri-
cans, and Hispanics [35]. Furthermore, various subsamples
weights for single two-year survey cycles are available for
specified sampling fractions, which accounts for the addi-
tional probability of selection into the subsample compo-
nent as well as the additional nonresponse [36].
Our analysis included data from the 2005–2006 and
2007–2008 NHANES cycles, as well as data from the
1999–2000, 2001–2002, and 2003–2004 NHANES cycles.
The 2005–2008 cycles included data of 20,497 people, the
1999–2004 cycle data of 31,126 people. We restricted the
analysis to participants 18? years old (n = 11,335 and
n = 16,183) to reduce variability in inflammation marker
levels. In addition, we excluded pregnant women (n = 351
and n = 687). After excluding participants with missing
information on urinary phytoestrogen levels, the sample size
for this study consisted of 3,174 and 4,263 individuals. From
these, all individuals reporting about acute infection (n = 744
and n = 1,129) were excluded. The final sample sizes from
individuals with CRP concentration B10 mg/L or WBC
counts C3.0 and B11.7 (1,000 cells/lL) were n = 2,028 and
n = 2,628 (rationale for cut-off levels see [34]).
The NHANES study protocols were approved by
National Center for Health Statistics (NCHS) Research
396 Cancer Causes Control (2014) 25:395–403
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Ethics Review Board (ERB), and informed consent was
obtained from all participants.
Measurements
Blood was drawn by venipuncture, and spot urine samples
were collected at NHANES mobile examination centers.
Urine specimens were processed, stored, and shipped to the
Division of Environmental Health Laboratory Sciences,
National Center for Environmental Health, Centers for
Disease Control and Prevention for analysis (for details see
NHANES Laboratory/Medical Technologists Procedures
Manual). Vials were stored under appropriate frozen
(-20 C) conditions until shipment to National Center for
Environmental Health for testing.
Urinary concentrations of lignans were measured by the
Nutritional Biomarkers Branch, Division of Laboratory
Sciences, National Center for Environmental Health,
Centers for Disease Control and Prevention. Comparable
methods for the determination of lignans were used [37].
During the 1999–2002 surveys, analyses were performed
by HPLC-APCI-MS building on the Barnes et al. [38]
method for phytoestrogens. During the 2003–2004 surveys,
they were analyzed by HPLC Electrospray Ionization MS
[37] and during the 2005–2008 cycles by HPLC-APPI-MS/
MS. Of the phytoestrogens measured in the five NHANES
cycles 1999/2000, 2001/2002, 2003/2004, 2005/2006, and
2007/2008, lignans represented by enterodiol and entero-
lactone were used for the present analysis.
Urinary concentration of creatinine, used to correct
urinary levels of analytes for urine dilution, was measured
using Beckman Synchron CX3 Clinical Analyzer at the
University of Minnesota [39]. Phytoestrogen concentra-
tions were expressed in lg/g creatinine.
C-reactive protein was measured by latex-based neph-
elometry by the Immunology Division, Department of
Laboratory Medicine, University of Washington Medical
Center. The CRP limit of detection was 0.2 mg/L for the
years 1999–2008, and 0.1 mg/L was assigned for CRP
levels below detection limit. WBC count was determined
using Beckman Coulter MAXM instruments in MECs with
the Beckman Coulter method of counting and sizing.
Weight and height were measured by trained personnel.
Body mass index (BMI) was calculated as weight in kilo-
gram divided by squared height in meter. Age, sex, alcohol
use, and smoking habits were self-reported and were asses-
sed by interviews. Race/ethnicity, hormone use, and acute
infection during the last 30 days (head/chest colds, stomach
or intestinal illness, flu, pneumonia, or ear infection) were
also part of an interview. Self-reported history of congestive
heart failure, coronary heart disease, heart attack, or stroke
was used to define prevalent cardiovascular disease (CVD)
and self-reported history of a diagnosis of cancer (other than
non-melanoma skin cancer) to define prevalent cancer.
Participants were considered as being diabetic when they
reported a history of a diagnosis of diabetes or were users of
insulin or diabetic medication. Self-reported history of
hypertension was assessed when the participants had been
told at least twice by a doctor to have hypertension and/or
when the participants were users of antihypertensive medi-
cation. History of kidney disease was assessed by the ques-
tion whether ever a doctor or other health professional told
the patient that he/she had weak or failing kidneys. Hormone
therapy was assessed by questions concerning intake (pills)
and patches of estrogen or estrogen/progestin.
Poverty–income ratio (PIR) was calculated as a pro-
portion of the self-reported family income to the United
States Census-based poverty threshold value for each cal-
endar year adjusted for inflation and the age of the family
reference person (a PIR value of 1 or greater indicates
income above the poverty level, whereas a PIR value
below value 1 indicates poverty). Women were considered
as postmenopausal when they were 55? years old.
Statistical analyses
Data were analyzed using survey methods in Stata statistical
software version 11.2 (College Station, TX) to account for
the complex NHANES sampling design. p \ 0.05 was
considered to be statistically significant (two-sided tests).
Sampling weights were applied according NHANES
guidelines to produce estimates that were representative of
the non-institutionalized, civilian US population [36].
We used medians for levels of lignans and percentages
for demographic variables. Log-transformend CRP con-
centration and WBC count by creatinine-standardized log-
transformed concentrations of lignans were used for linear
regression. In linear models, where both the dependent and
the independent variables have been log-transformed, the
dependent variable can be interpreted as percentage chan-
ges for a one-percent increase in the independent variable,
while all other variables in the model are held constant. In
the demographic-adjusted model, we adjusted for sex [40,
41], age (continuous) [40, 41], and race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic/Mexican
American, other) [40, 42]. In the multivariable-adjusted
model, we first adjusted additionally for BMI (continuous)
[41, 43], alcohol consumption (no drinks, B1 drink per
week,[1 drink per week) [41], menopausal status (yes/no)
[44, 45], current hormone therapy (HT) use (yes/no) [44,
46], cigarette smoking status (never, former, or current
smoking) [41, 47], PIR (\1 vs. C1) [41, 48], and chronic
diseases (yes/no for kidney disease, cancer, hypertension,
diabetes and CVD) [6, 49–52]. The covariates were chosen
a priori based on known or suspected confounders of the
relationship of lignans and inflammation.
Cancer Causes Control (2014) 25:395–403 397
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Table 1 Baseline characteristics of individuals, aged 18? years, with data on C-reactive protein (CRP) blood concentrations, white blood cell
counts (WBC), and urinary lignans in NHANES 1999–2004 and 2005–2008a
2005–2008 1999–2004
median Q1 Q3 median Q1 Q3
Phytoestrogens (lg/g creatinine)
Lignansb 501.0 187.3 1,089.5 436.8 172.9 958.6
Enterodiol 41.5 15.9 105.0 37.0 14.8 84.2
Enterolactone 418.4 119.3 973.9 374.6 122.4 852.1
C-reactive protein (CRP; mg/L) 1.5 0.6 3.2 1.8 0.7 3.5
White blood cell count (WBC; 1,000 cells/lL) 6.8 5.6 8.0 6.7 5.6 8.0
Age (years) 49 34 64 46 32 65
% %
Sex (women) 48.1 48.5
Race
Non-Hispanic white 72.7 73.8
Non-Hispanic black 10.5 9.4
Mexican American 7.4 7.3
Other 9.3 9.5
Poverty–income ratio (PIR)
Below poverty (\1) 9.7 11.4
At or above poverty (C1) 84.2 81.7
Missings 6.1 6.9
Smoking history
Current smoker 20.9 21.5
Former smoker 25.5 24.3
Never 51.9 52.3
Missings 1.8 1.9
Average number of alcoholic drinks/day—past 12 months
0 38.0 36.1
B1 29.1 29.3
[1 32.9 34.7
BMI kg/m2
\18.5 2.1 1.5
C18.5–\25.0 32.8 33.2
C25.0–\30.0 34.5 34.6
C30 29.7 28.8
Missings 0.8 2.0
Hormone therapy in menopausal women 9.3 22.4
Postmenopausal status in women 34.6 31.0
Chronic diseasesc
History of diabetes 7.6 6.0
History of hypertension 30.0 38.6
History of cancer 8.1 6.6
History of CVD 7.8 7.0
History of kidney disease 1.2 0.6
a Values are weighted except medians
b Enterodiol, enterolactone
c Self-reported
398 Cancer Causes Control (2014) 25:395–403
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We compared the distributions of the above-mentioned
covariates in individuals of our sample (n = 2,028 and
n = 2,628 for the years 2005–2008 and 1999–2004,
respectively) with those in individuals aged 18? not
included in our sample (n = 9,307 and n = 13,555 for the
years 2005–2008 and 1999–2004, respectively) to evaluate
differences between these two groups. Furthermore, we
stratified the analyses by gender as a sub-analysis.
Results
Table 1 summarizes socioeconomic, lifestyle, and health
characteristics of the study population by the two study
periods 2005–2008 and 1999–2004. Of the middle-aged,
mainly non-Hispanic whites, nearly half were smokers or
former smokers, one-third were drinking more than one
drink alcohol per day and about one-third had a history of
hypertension, and less than 10 % were affected by a history
of CVD, cancer, diabetes, or kidney disease. About one-
third of the included women were postmenopausal. Com-
paring our sample with the non-included individuals in the
same age range in the two study periods, the median level
of CRP was similar (1.5 vs. 2.2 mg/L in 2005–2008 and 1.8
vs. 2.4 mg/L in 1999–2004) as well as the median WBC
count (6.8 vs. 7.1 9 1,000 cells/lL) in 2005–2008 and 6.7
vs. 7.1 9 1,000 cells/lL in 1999–2004). Other demo-
graphic and lifestyle factors were similarly distributed
between the two groups (data not shown).
Table 2 shows the associations of urinary lignans con-
centrations with CRP concentrations and WBC counts for
the time periods 2005–2008 and 1999–2004, respectively.
In both periods, we observed statistically significant
inverse associations of urinary total lignan, enterodiol, and
enterolactone levels with CRP concentrations and WBC
counts, in the demographic-adjusted models. However,
these associations were partly attenuated in the multivari-
able-adjusted models, such that enterodiol was not signif-
icantly associated with CRP concentration in the
multivariable-adjusted models in the analysis of data of the
2005–2008 and the 1999–2004 cycles; the same was true
for enterodiol and enterolactone in the analysis of data
from 1999 to 2004. Per one-percent increase in urinary
lignan concentrations, CRP concentrations and WBC
counts decreased by 8.1 % (95 % CI -11.5, -4.5) and
1.9 % (95 % CI -2.7; -1.2), respectively, in the multi-
variable-adjusted models of the period 2005–2008. Per
one-percent increase in enterodiol and enterolactone, WBC
counts decreased by 2.1 % (95 % CI -2.8, -1.3) and
1.3 % (95 % CI -1.9, -0.6), respectively. Per one-percent
increase of enterolactone, CRP concentrations decreased
by 7.1 % (95 % CI -9.9, -4.3). In NHANES 1999–2004,
per one-percent increase in lignan concentrations in urine
resulted in a 3.0 % (95 % CI -5.6, -0.3) decrease in CRP
concentration and 1.2 % decrease in WBC count (95 % CI
-2.0; -0.4). Per one-percent increase in enterodiol and
enterolactone, WBC counts decreased by 1.0 % (95 % CI
-1.8, -0.2) and 0.8 % (95 % CI -1.4, 0.2), respectively.
When analyses were stratified by gender, there were
slightly higher, significant associations in women than in
the total sample (NHANES 1999–2004). In NHANES
2005–2008, results were similar for men and women as
well as for the total sample. There were not significant
interactions between sex and any of the phytoestrogen
(data not shown).
Discussion
In the present study, urinary mammalian lignans were
significantly inversely related to serum CRP levels and
WBC counts, suggesting a possible inverse association
between lignans and inflammation. This was true for both
time periods studied (NHANES 2005–2008 and NHANES
1999–2004). The associations were maintained after con-
trolling for important factors that may have confounded the
associations. To the best of our knowledge, the cross-sec-
tional association of urinary lignans with CRP concentra-
tions and WBC counts has not yet been examined in other
studies. Our findings may be of interest for example in the
context of prospective studies having shown a higher risk
of developing cardiovascular diseases and cancer in those
with elevated serum CRP [53].
We recently evaluated the association between urinary
genistein, daidzein, O-DMA, and equol excretion and CRP
levels, and WBC counts in adults in the United States in the
National Health and Nutrition Survey (NHANES) 2005–2008,
but no clear pattern emerged, although higher excretion of
some soy isoflavonoids was associated with decreased CRP
concentration and WBC counts [34]. In relation to lignans,
Valentin-Blasini et al., using urinary phytoestrogen concen-
trations in NHANES 1999–2000, observed [40] the highest
urinary concentrations of all phytoestrogens measured for
enterolactone, and these values correlated with levels reported
for other populations [54]. As already mentioned in the intro-
duction, only a few studies investigated the association
between lignans and CRP levels and the results are not con-
sistent [30–32]. Hallund et al. [30] evaluated 2008 the effects of
a plant lignan complex isolated from flaxseed, providing
500 mg/d of secoisolariciresinol diglucoside, on inflammatory
markers. They found that daily consumption of a low-fat
muffin enriched with a lignan complex for 6 weeks reduced
CRP concentrations significantly compared to a low-fat muffin
with no lignans added. Dodin et al. [31] evaluated in 2008 the
effect of 40 g of flaxseed versus wheat germ placebo on
markers of cardiovascular disease risk in healthy menopausal
Cancer Causes Control (2014) 25:395–403 399
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women. The values of CRP did not change significantly after
12 months of treatment. Pan et al. [32] explored the effects of
lignans (360 mg flaxseed-derived secoisolariciresinol dig-
lucoside daily) on inflammatory factors in type 2 diabetics,
who have in general higher levels of these biomarkers. Base-
line to follow-up concentrations of CRP increased significantly
within the placebo group, but was comparatively unchanged in
the lignan-supplemented group; a significant difference was
observed between treatments. This effect was observed in
women, but not in men. Potential explanations for these sex
differences might be the relatively small sample of males, but
also the possibility that postmenopausal women were more
likely to be responsive to phytoestrogens [32]. In the present
study, there were no significant interactions between sex and
phytoestrogens, thus sex differences in NHANES 1999–2004
must be due to chance finding.
In the present study, we observed a significantly inverse
association between urinary lignans and CRP concentra-
tions and WBC counts.
However, the mechanisms of these associations are still
unknown. One suggested effect could be that lignans and
their metabolites, enterodiol and enterolactone, may affect
CRP concentrations due to their antioxidant activity, which
have been shown in different in vitro model systems [30].
For example, lignans have been shown to be able to lower
lipid peroxidation and reduce deoxyribose oxidation and
DNA strand breakage [55].
Our study has several strengths. For evaluating the
associations of urinary lignans with CRP levels and WBC
counts, we used data from a nationally representative
sample of individuals (NHANES 2005–2008 and
NHANES 1999–2004). Furthermore, urinary lignan values
comprise phytoestrogen intake from all sources, which is
very difficult to assess by a dietary survey. Urinary lignan
measurements also take into account the capacity to pro-
duce enterolignans. In addition, the latex-based nephe-
lometry used in the present study to assess serum CRP has
a much lower detection limit than previously used methods.
This survey has also some important limitations. We
adjusted our findings for alcohol intake, physical activity,
smoking, BMI, age, gender, race, and poverty–income ratio
to control confounding by sociodemographic factors and a
healthy lifestyle. Residual confounding due to unmeasured
or unknown factors is nevertheless a potentially important
bias in our study. In a cross-sectional study of 468 US male
health professionals [56], the main food groups for total
lignan intake were tea and coffee (28 %), noncabbage,
nonlettuce vegetables (11 %), alcoholic beverages (9 %),
and bread, cereals, rice, and grains (7 %). Thus, residual
confounding due to other dietary constituents in coffee, tea,
vegetables, grains, etc. (dietary fiber, antioxidant vitamins,
other flavonoids, etc.) cannot be excluded. Furthermore,
most variables included in the multivariable models were
self-reported. Recall and misclassification bias cannot be
excluded. Our reduced sample of individuals due to miss-
ing information on phytoestrogen level is a further critical
point. Nevertheless, the comparison of individuals of our
sample with individuals of the same age range not included
in our sample showed that the distribution of most demo-
graphic and lifestyle characteristics and the levels of CRP
and WBC count were similar.
Additionally, CRP concentrations and WBC counts are
affected by infection, acute, or chronic conditions. We
excluded all individuals reporting acute infection and all
participants with high circulating CRP ([10 mg/L) con-
centrations and WBC counts (\3.0 and [11.7 (1000 cells/
lL)) from our analyses. In addition, we controlled for those
with self-reported select chronic conditions, but there could
still be confounding by medication. The potential impact of
menstrual cycle variability on CRP levels, observed for
example by Gaskins et al. [57] in the BioCycle Study; we
were not able to assess in the present study. This may lead
to under- or overestimation of the observed associations or
be of no impact. Most probably, the latter is true because
there is, to our knowledge, no evidence available that lig-
nan intake/urinary excretion is related to the menstrual
cycle.
In conclusion, our results indicate that in US adults
mammalian lignans were associated with a beneficial pro-
file of inflammatory markers (CRP, WBC), although cau-
sality cannot be inferred in these cross-sectional analyses.
Our findings warrant further investigation in this field, on
the one hand by using cellular and animal models to
identify the exact biological mechanisms, and on the other
hand by carrying out cohort and intervention studies in
humans to establish causality of the observed associations.
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